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Abstract. Background/Aim: Heparanase (HPA) contributes
to breast cancer metastasis by facilitating the breakdown of
the basement membrane and extracellular matrix. High
expression of HPA is thought to be associated with increased
nodal involvement and poor survival in patients with breast
cancer. Overexpression of cyclooxygenase-2 (COX-2) in
breast cancer is associated with indicators of poor prognosis
such as lymph node metastasis, poor differentiation, and
large tumor size. The underlying mechanism by which HPA
and COX-2 overexpression increases the metastatic potential
of breast cancer is not fully-understood. To enhance our
understanding over these mechanisms, we aimed to
investigate the relationship between the size of the tumor and
HPA expression, tumor grade as well as lymph node status
in patients with breast cancer. Materials and Methods:
Immunohistochemical analysis of HPA and COX-2
expression was performed on 246 breast tumor samples. The
expression of HPA was correlated with COX-2 expression,
tumor grade, lymph node status, oestrogen receptor status.
Results: The overexpression of HPA and COX-2 was
associated with increased likelihood of lymph node positivity
in large, high-grade tumors. High-grade tumors with size
greater than 20 mm, that overexpressed HPA, were 4-times
more likely to be associated with lymph node involvement
(OR 4.71, CI 1.21-18.25). Whereas, tumors greater than 
20 mm in size were 5-times more likely to metastasize to the
regional lymph nodes, if associated with overexpression of
COX-2 (OR 5.5, CI 1.2-24.8). Conclusion: Expression of
HPA appears to be a key mechanism by which large, high-
grade breast tumors metastasize to regional lymph nodes,
while COX-2 overexpression may be an independent
predictor of lymph node positivity. 
Heparanase (HPA) is a β-endoglucuronidase enzyme that acts
on heparan sulphate (1), the main polysaccharide component
of the extracellular matrix, leading to the degradation of
adhesion molecules and breakdown of the extracellular matrix
and basement membrane (2) aiding invasion (3-5). It is
suggested that HPA may have a role in facilitating both tumor
cell invasion and neovascularization, two critical steps in
tumor progression. In addition, HPA overexpression may lead
to tumor growth and angiogenesis (6-10). It is suggested that
destruction of the basal membrane and formation of new blood
vessels may be the foundation for HPA involvement in tumor
formation. Cyclooxygenase-2 (COX-2) is overexpressed in a
variety of malignant tumors including breast cancer.
Overexpression of COX-2 in breast cancer is associated with
indicators of poor prognosis such as lymph node metastasis,
poor differentiation, and large tumor size (11). 
Axillary lymph node metastases remain the most important
prognostic factor for breast cancer. If predictive accuracy of
the metastatic potential of breast cancer can be enhanced, this
will provide useful information for patients and healthcare
professionals to make informed choices regarding local and
systemic treatment planning. It remains an on-going challenge
to identify biological factors that may enhance the
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predictability of lymph node metastasis of breast cancer.
Larger size of the tumor, higher histological grade and young
age are recognised predictors of axillary lymph node
metastases. However, the underlying mechanism by which
these biological variations affect the capacity of a breast tumor
to spread to regional lymph nodes is not fully understood. 
COX-2 and HPA can potentially provide additional
information to identify patients at an increased risk of lymph
node metastasis, The experimental studies in transgenic mice
found that expression of HPA was associated with branching
of ducts and alveolar development in mammary glands (12).
Given the role of these molecules in cell invasion and
angiogenesis, it is plausible that increased nodal metastasis
in larger breast cancer is mediated by HPA and COX-2
expression. The aim of the present study was to investigate
the relationship between the size of the tumour and HPA
expression, tumour grade as well as lymph node status in
patients with breast cancer.
Materials and Methods
Archived tissue samples from cases with and without nodal
metastasis treated for breast cancer at a large Teaching Hospital in
the UK, for the period between 1st January 2000 and 31st December
2004 were included in the study. The mean age at diagnosis in the
study was 64 (range=30-90) years.
Immunohistochemical analysis of HPA and COX-2 expression was
performed on 123 pairs (one with metastasis, one without) of breast
tumor samples matched for age (±1 year) and tumor size (±1 mm).
Immunohistochemistry for HPA was carried-out on the paraffin-
embedded, formalin-fixed breast cancer tissue using the Bondmax
(Vision Biosystems: Leica Biosystems Newcastle Ltd, Balliol Business
Park West, Newcastle Upon Tyne, NE12 8EW United Kingdom)
automated staining machine using standardised techniques. Antigen
assessment was carried out on each case using the Heparanase
antibody (HPA-1; Insight Laboratories, diluted 1:50 with Bondmax
antibody diluent, Vision Biosystems: AR9352) and Cyclooxygenase-II
antibody (COX-2; Abcam Laboratories; ABCAM, 330 Cambridge
Science Park, Cambridge, CB4 0FL, UK, diluted 1:75 with Bondmax
antibody diluent). Slides for HPA immunohistochemical analysis were
examined microscopically and scored 0 for negative and 1 for positive
according to visualisation of the brown chromagen precipitate. Slides
for COX-2 immunohistochemical analysis were examined
microscopically and each slide was scored on a scale of 0-3 according
to the staining intensity of the reaction (0=negative; 1=weakly positive;
2=moderately positive; 3=strongly positive). Scoring was carried out
by the chief investigator and an independent colleague. Results were
compared and discrepancies were discussed and decided upon using a
double-headed microscope.
Statistical analysis was performed on the completed dataset of
246 patients using PASW Statistics 18 software (SPSS Inc.,
Chicago, Illinois, USA). Lymph node (LN) status was explored
using conditional binary logistic regression (when patients were
matched on age (±1 year) and tumour size (±1 mm) variables). The
4 explanatory variables were Grade of Tumour, ER status,
heparanase and COX-2 expression and selected 2nd order
interactions. Backward elimination was used to obtain the
parsimonious solution. In order to further clarify the identified
solution, cross-tabulations were used with the associated Chi-
squared statistics. A p-value <0.05 denoted the presence of a
statistically significant difference.
Results
The mean age at diagnosis in the study was 64 (range 30-90)
years. For patients with large tumors (>20 mm), the
conditional binary logistic regression analysis identified that
patients with COX-2 overexpression were 5-times more
likely to have a metastasis to the regional lymph nodes (OR
5.5, CI 1.2-24.8). Again, only for patients with large tumors
(>20 mm), the conditional binary logistic regression analysis
identified that patients that were diagnosed with
overexpressed HPA (heparanase-positive) and had high-grade
tumors were nearly 5-times more likely to be associated with
lymph node involvement (OR 4.71, CI 1.21-18.25). This
interaction can be more clearly understood in Table I (Chi-
square=6.29; p=0.012). Seventy-five percent of all high-
grade tumors that had overexpressed HPA were associated
with positive lymph nodes.
The above differences and assocations were retained in the
model when a multivariable analysis was performed using
backward elimination.
Discussion
The present study demonstrates the novel finding that in our
cohort of breast cancer patients, overexpression of HPA in
high-grade large tumors was associated with increased
incidence of regional lymph node metastases. This suggests
that HPA expression is a key mechanism in the metastasis of
high grade breast cancer. In breast tumors, that did not over-
express HPA, we found no association between non-high
tumors and lymph node status or between high grade tumors
and lymph node status. 
It is well-recognised that tumor histological grade can be
associated with metastasis and poor disease outcome (13).
HPA has established proliferative, invasive and metastatic
properties (14). Previous studies have suggested that HPA
expression in breast cancer tumors is tumor size- (10) or ER-
dependent (15) and HPA expression is also positively
correlated with breast cancer tumor grade (16). Our data add
to the field by suggesting that poorly-differentiated tumors
use increased HPA expression as a key mechanism to initiate
or propagate metastasis to regional lymph nodes.
As the association between overexpression of the HPA
and lymph node metastases was only found in large, high-
grade tumors, it is postulated that high grade tumors are
more capable of expressing and secreting HPA which in
turn may facilitate cell proliferation and metastasis, leading
to an increased ability to spread to distant sites. Evidence
from transgenic animal experiments, whereby
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overexpression of HPA in tumors of low metastatic
potential cells conferred a high metastatic potential, also
supports this hypothesis (17). 
Our study is in concordance with what is reported in the
literature, that HPA is a potent tumor modulator due to its pro-
tumorigenic, pro-angiogenic, and pro-metastatic activities (18).
However, we found that this association was limited to large,
high-grade tumors. The differences in patterns of progression
of various grades and types of breast cancer is a well-
recognised phenomenon (19); our data add to the current
understanding by showing that in high-grade tunours HPA
overexpression contributes to nodal metastases. There is always
a possibility of a Type I error due to small numbers, however
our results are supported by clinical experience. In clinical
practice, high-grade tumors are more likely to be associated
with lymph node positivity (20). The hypothesis generated by
a study of positive sentinel nodes that HPA may be involved in
lymph node positive tumors (21) is supported by our data
which demonstrate that HPA expression in high grade breast
cancer may lead to lymph node positivity (4, 15, 22).
Past studies have demonstrated that there is a significant
relationship between HPA, COX-2 and angiogenesis. The
present study does not reveal a correlation between HPA
expression and COX-2 expression (data not shown). The
present study, however, supports previous studies which
demonstrate that COX-2 is not correlated with ER status (23). 
In conclusion, the present study has shown that expression
of HPA appears to be a key mechanism by which large, high-
grade breast tumors metastasize to regional lymph nodes,
while COX-2 overexpression is an independent predictor of
lymph node positivity. 
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